The Scanner Magazine Issue 36

download The Scanner Magazine Issue 36

of 52

  • date post

    07-Mar-2016
  • Category

    Documents

  • view

    229
  • download

    5

Embed Size (px)

description

monthly medical magazine

Transcript of The Scanner Magazine Issue 36

  • SCANNERthe I & 36

    -

    20

    10

    www. t h e s c a n n e rma g a z i n e . c om

    scanner36L.indd 1 04/10/2010 12:27 ..

  • scanner36L.indd 2 04/10/2010 12:28 ..

  • E D I T O R I A L

    : , : , , , , , , K T B, (), Denis Gaumondie ()

    : (11 ): 180 20% 50%. : .: +30 210 6753096 - +357 22458500 FAX: +30 210 6753097 e-mail: kazassis@hol.gr, fabioltd@otenet.gr

    www.thescannermagazine.com 2 . : inhealco@otenet.gr : ZEVGARIDOU + ASSOCIATES, .: 210 6721778/9

    & Fabio Holdings Ltd.,11 oumpoulinas Street, 1060 Nicosia, CYPRUS, Copyright 2010

    3

    , , . , : ().

    : () () ()...

    , .

    4 6 - 8 16 17 18 19 21 22 24 26 28 29 GADGETS 30 31 32 34 36 & 40 42 44 46 48 49FACTFILE 50

    scanner36L.indd 3 04/10/2010 12:28 ..

  • Human care makes the future possible

    Beyond technology theres possibility

    Elekta Axesse Leksell Gamma Knife Perfexion

    Extend program

    Over 40 years ago Professor Lars Leksell invented Gamma Knife surgery, a revolutionary, non-invasive way to perform brain surgery that created new treatment possibilities for patients with inoperable brain cancer. Today, Leksell Gamma Knife Perfexion is the cornerstone of a complete line of stereotactic treatment and radiosurgery solutions that is still creating new possibilities for the most challenging cases of the brain, head & neck, and body. Find out more at elekta.com/proof.

    Stereotaxy 205 x 270 4mm bleed.indd 1 28/06/2010 14:52

    4

    scanner36L.indd 4 04/10/2010 12:28 ..

  • Human care makes the future possible

    Beyond technology theres possibility

    Elekta Axesse Leksell Gamma Knife Perfexion

    Extend program

    Over 40 years ago Professor Lars Leksell invented Gamma Knife surgery, a revolutionary, non-invasive way to perform brain surgery that created new treatment possibilities for patients with inoperable brain cancer. Today, Leksell Gamma Knife Perfexion is the cornerstone of a complete line of stereotactic treatment and radiosurgery solutions that is still creating new possibilities for the most challenging cases of the brain, head & neck, and body. Find out more at elekta.com/proof.

    Stereotaxy 205 x 270 4mm bleed.indd 1 28/06/2010 14:52

    Elekta . 17-19 & . 42, 151 24 , . 210 8067901, Fax: 210 8067911 www.elekta.com

    Human care makes the future possible

    scanner36L.indd 5 04/10/2010 12:28 ..

  • tThe global insulin pump market was valued at $586.4m in 2009, and is forecast to grow at a compound annual growth rate (CAGR) of 9% from 2009 to 2016. The growth in the market is primarily being driven by increases in the elderly population and obesity rates, advances in technology (the emergence of an artificial pancreas and an insulin and glucagon delivery system) and rising patient awareness.

    . Insulin pump market global revenue ($m) forecast for 2009-2016

    US market

    The US insulin pump market is expected to reach $843m in 2016, growing at a CAGR of 9% from 2009 to 2016. The traditional insulin pump segment was valued at $394m in 2009 and the disposable insulin pump segment was valued at $58.9m in 2009. The US remains the largest market. This market is going to be driven by the increased penetration of well established players and next generation pumps such as artificial pancreases and the simultaneous delivery of insulin and glucagon.

    Increasing prevalence of diabetes to drive the marketDiabetes results in nearly four million deaths every year. The International Diabetes Federation (IDF) estimates that by 2025, nearly 380 million people worldwide will have diabetes. The diabetic population is going to grow in developing countries due to people leading more sedentary lives, changes in diet and urbanization.

    Medtronic and Roche dominateSeven out of the ten countries with the highest number of people with diabetes are in the developing world. China, India and the US constitute the majority of the diabetic population. The obesity rate has increased globally over the past few decades. Currently, more than one billion adults are overweight worldwide, which is a major risk factor for diabetes. This increases the prevalence of diabetes and is expected to drive the insulin pump market.

    The lead supplier is Medtronic with 58% of the market in 2009. Medtronics MiniMed Paradigm sells well and was the first insulin pump to be integrated with the companys Real-Time Continuous Glucose Monitoring (CGM) system and so provides tighter control over glucose levels and gives a better quality of life.

    Roche is the second largest supplier with a market share of 12%. Roches Accucheck spirit insulin pump has shown strong growth due to features such as three operating menus, four bolus options, five basal rate profiles and smaller size.

    MiniMed (Medtronic) and Disetronic Medical Systems (Roche) were major players in the segment

    6

    scanner36L.indd 6 04/10/2010 12:28 ..

  • 7until the year 2000. The market subsequently fragmented with the entry of companies such as Animas Corporation with its R1000 insulin pump and eltec with its Cozmo insulin pump. The acquisition of MiniMed, which was the leading manufacturer of insulin pumps in the US, by Medtronic, and the acquisition of Disetronic, one of the largest insulin pump manufacturers in Europe, by Roche, helped these companies to regain their shares and dominate the worldwide insulin pumps market.

    Animas Corporation currently has a global market share of 11% giving close competition to Insulet Corporation with the global market share of 10%. As Insulet is the only company currently offering disposable insulin pumps, it has quickly gained market share since its market entry in 2005.

    Technological advances drive the marketProducts such as artificial pancreases, disposable insulin pumps, insulin patch pumps, nanopumps and insulin, glucagon delivery pumps are under development. These are expected to be more

    efficacious, smaller in size and to be less likely to malfunction than the currently marketed products.

    Feature such as the use of an algorithm for intelligent monitoring enable exceptional overnight control of glucose levels without any incidence of hypoglycemia and enable patients to regulate their blood glucose as well as a functioning pancreas system. The insulin glucagon delivery system also helps to control blood sugar levels without hypoglycemia, even after high-carbohydrate meals. These technological advances are expected to drive the insulin pumps market.

    Company share of the global insulin pump market (% by revenue), 2009.

    A

    PHMTvoE

    OIMENIONAPHAEONTATIMAINEMONTATEAIABIITYOINTAAIAOPATENINNEBONINANT

    scanner36L.indd 7 04/10/2010 12:28 ..

  • 8

    -

    1980 1990 - 1980 20% -. 1990 80% 1993 120%. 100-120% .

    , 1990, - - . - 11 , 1994 1998. - , 3605/93 (), .

    - 1997 - - , - . - , - .

    , , 18% . , . , - , - 2001 2004. -. , , , - . 30 - , 550 , - 1994.

    , - - , , . - , , , -

    scanner36L.indd 8 04/10/2010 12:28 ..

  • 9 . - , , - , - , 94, 95 96. - , 3%. - 2469 . : , , - , -. 1 5 1:1, 1.1.1997 , . , , 1996-1998, , - - , ... . , ..

    .

    1997, - /. - 13.6% 1998 .

    2000 1 2001 - .

    2001 - 1997, - 50%. 31 2001 100 900 . . , , , , - , . - , 2000, 4,1% 2001 - 6%, - 100% 14 . , - . , , -

    scanner36L.indd 9 04/10/2010 12:29 ..

  • - 10

    , .

    1 2002 , - , - - . -, , , , . , 2004, -, , . -. , , 166/03 , , , , .

    - . 1997-2003, - , , , - Eurostat.

    , - , , 900 , 2001.

    2004 - . -, , - . 1 2001 31 2004.

    7,5%, . , 2,2 , 1,2 % . 2004 .

    2005 - 1 2001 31 2004 2,5 . - 2005 . - .

    2005, : -

    scanner36L.indd 10 04/10/2010 12:29 ..

  • 11

    . , , , -, , ,